Katherine Szarama, a close ally of former FDA biologics chief Vinay Prasad, has stepped down as acting director of the Center for Biologics Evaluation and Research (CBER) after less than three weeks in the role.
Szarama’s departure is part of a broader leadership shake‑up at the FDA following the exit of Commissioner Marty Makary and other senior officials, including Tracy Beth Høeg, acting head of the drug center (CDER).
Szarama will reportedly remain at the FDA in another capacity, working on product‑related issues, even though her status during the transition was initially unclear.
Sources:
CBER chief Prasad steps aside, deputy takes the reins - Fierce Biotech
FDA Makes Leadership Overhaul Following Commissioner Makary's ...
Center for Biologics Evaluation and Research (CBER) - FDA
FDA Shakeup: Høeg Fired, Davis Named Acting CDER Head
FDA Names New Director for Vaccines, Biologics Unit - NPHIC
FDA Leadership Shift: Katherine Szarama's Departure and ... - BioIntel
FDA shuffles leadership following Makary's exit
US FDA taps Szarama as acting head of vaccine unit - WDEZ
Prasad ally Szarama exits CBER after 3 weeks as FDA cleanout ...
FDA names Katherine Szarama acting director of CBER - STAT News
US FDA taps Szarama as acting head of vaccine unit, Politico ...